PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast - Christian T. Ruff, MD, MPH - Making the Connection: A Call to Action Against Undiagnosed Atrial Fibrillation—Improving Detection, Reducing Risk

Christian T. Ruff, MD, MPH - Making the Connection: A Call to Action Against Undiagnosed Atrial Fibrillation—Improving Detection, Reducing Risk

05/08/20 • 35 min

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Go online to PeerView.com/NTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiology discusses best practices for the screening, diagnosis, and treatment of atrial fibrillation to reduce thromboembolic risk. Upon completion of this activity, participants will be able to: Recognize the prevalence of undiagnosed atrial fibrillation (AF) in patients 65 years and older at risk for AF and stroke, Discuss the need for opportunistic and systematic screening for AF among individuals 65 years of age and older and at high risk for AF and stroke, Employ various screening methods routinely in clinical practice to ensure that patients at risk for AF and stroke are diagnosed, Apply guideline recommendations as well as safety, efficacy, and real-world data on non–vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic risk reduction in patients with AF.

Previous Episode

undefined - Harry P. Erba, MD, PhD/James M. Foran, MD, FRCPC - The Continuing Wave of Innovation in AML: Getting the Most From the Convergence of Novel Therapy and Allogeneic Transplant

Harry P. Erba, MD, PhD/James M. Foran, MD, FRCPC - The Continuing Wave of Innovation in AML: Getting the Most From the Convergence of Novel Therapy and Allogeneic Transplant

Go online to PeerView.com/WRR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent wave of therapeutic innovation in the management of patients with acute myeloid leukemia (AML) has had implications for many different patient populations, including those who are eligible for allogeneic hematopoietic stem cell transplantation (HCT). Most evidence currently supports a management model that includes the use of newer cytotoxic formulations, novel antibodies, and targeted and epigenetic compounds in conjunction with HCT (eg, as newer induction, conditioning, or maintenance strategies). This expert-led activity, based on a live educational MasterClass held during the 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, explores these new developments and provides insights on the evidence that continues to support the integration of recent therapeutic innovations into the management of transplant-eligible AML populations. This program also features case-based illustrations of how to adapt or refine current induction, conditioning, and post-HCT maintenance protocols by utilizing the wealth of new agents available for patients and clinicians. Upon completion of this activity, participants should be better able to: Cite current guidelines for transplant eligibility and the use of novel therapeutics as induction, pre-transplant conditioning, or post-HCT maintenance for AML, Summarize updated evidence surrounding innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Recommend evidence-based regimens with novel components as part of a treatment plan that includes allogeneic HCT for patients with AML.

Next Episode

undefined - Farnaz Dadmanesh, MD - Increasing Importance of HER2 and HER3 Testing in the Context of an Expanding Targeted Therapies Landscape for Breast, Gastrointestinal, Lung, and Other Cancers: Latest Updates and Practical Guidance for Pathologists

Farnaz Dadmanesh, MD - Increasing Importance of HER2 and HER3 Testing in the Context of an Expanding Targeted Therapies Landscape for Breast, Gastrointestinal, Lung, and Other Cancers: Latest Updates and Practical Guidance for Pathologists

Go online to PeerView.com/SMP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the evolving era of precision cancer care, increasing emphasis is placed on detecting molecular alterations driving the development of specific cancers and targeting them with matched therapies or combinations that can yield the best outcomes for patients. Such is the case with HER2—and, more recently, also HER3 and TROP2—which are gaining growing interest as relevant targets in different malignancies. This is particularly important now, as a number of new targeted therapies have started to reach the clinic and are expected to change practice, and many others are showing great promise in clinical trials in breast, gastrointestinal, lung, and other tumors. Pathology professionals play an essential role in realizing the potential of precision cancer care by carrying out optimal predictive testing. This PeerView on-demand activity, based on a recent symposium at the United States and Canadian Academy of Pathology (USCAP) 108th Annual Meeting, features a panel of leading pathology and oncology experts, who share their insights into recent advances in testing and treatment of various HER2-altered cancers, including breast, gastrointestinal, lung, and other tumors. The emerging roles of HER3 and TROP2 as potential new targets are reviewed as well. In addition, they provide useful guidance to improve testing and best practices for interpretation, as well as interdisciplinary collaboration, all for the benefit of the patients. Upon completion of this activity, participants should be better able to: Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, non–small cell lung, and other cancers, Evaluate the characteristics, mechanisms of action, and efficacy/safety evidence of established and emerging HER2-targeted agents for the management of patients with advanced HER2-expressing or HER2-mutant cancers, Implement appropriate methods and best practices for HER2 testing and interpretation to guide integration of the latest HER2-targeted therapies into individualized treatment plans for patients with advanced HER2-expressing or HER2-mutant cancers either in the context of clinical practice or through clinical trial participation.